Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Conditions
- CNS Embryonal TumorCNS, MedulloblastomaAtypical Teratoid Rhabdoid TumorMedulloblastoma, ChildhoodMedulloblastoma, Group 3Medulloblastoma, Group 4PineoblastomaEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepithelioma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 15
- Registration Number
- NCT06942039
Allo HSCT for High Risk Hemoglobinopathies
- Conditions
- Graft FailureSickle Cell DiseaseHemoglobinopathies
- Interventions
- Radiation: Total Body IrradiationBiological: Cell Infusion
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 62
- Registration Number
- NCT06872333
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: Drugs Cyclophosphamide
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06807606
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Procedure: Autologous Stem Cell TransplantDrug: Anthracycline-based induction chemotherapy
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT06687772
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
- Conditions
- Acute Myelogenous LeukemiaAcute Lymphatic LeukemiaChronic Myelogenous LeukemiaMyelodysplastic SyndromesMyelodysplastic Syndrome OtherChronic Myelomonocytic LeukemiaLymphomaHodgkin Lymphoma
- Interventions
- Radiation: Total Body IrradiationBiological: Double Umbilical Cord Transplant
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 20
- Registration Number
- NCT06680661
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma
- Conditions
- Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT06625359
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Xianmin Song, MD
- Target Recruit Count
- 50
- Registration Number
- NCT06468267
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
- Conditions
- Hematologic MalignancyGraft Versus Host Disease
- Interventions
- Drug: CycophosphamideDrug: Anti-ThymoglobulinOther: Donor Lymphocytes InjectionRadiation: total body irradiationOther: hematopoietic stem cellsOther: Graft nuclear cells
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06252870
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Brest, Brest, France
🇫🇷CHU Nantes, Nantes, France
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Dual-Energy Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201Radiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT06195891
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Ganglioneuroblastoma, NodularNeuroblastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationProcedure: Tumor Resection
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.